These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 16925494)
1. Controversial issues and optimal management of stage T1G3 bladder cancer. Metwalli AR; Kamat AM Expert Rev Anticancer Ther; 2006 Aug; 6(8):1283-94. PubMed ID: 16925494 [TBL] [Abstract][Full Text] [Related]
2. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
4. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Kulkarni GS; Hakenberg OW; Gschwend JE; Thalmann G; Kassouf W; Kamat A; Zlotta A Eur Urol; 2010 Jan; 57(1):60-70. PubMed ID: 19740595 [TBL] [Abstract][Full Text] [Related]
5. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. Kim JC; Steinberg GD J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460 [TBL] [Abstract][Full Text] [Related]
6. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony]. Steinbach F; Schuster F Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407 [TBL] [Abstract][Full Text] [Related]
8. Management of the first recurrence of T1G3 bladder cancer: does intravesical chemotherapy deserve a chance? Witjes JA Urol Oncol; 2009; 27(3):322-4. PubMed ID: 19414122 [TBL] [Abstract][Full Text] [Related]
9. The management of superficial bladder cancer. Dalbagni G Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810 [TBL] [Abstract][Full Text] [Related]
10. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080 [TBL] [Abstract][Full Text] [Related]
11. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts. Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729 [TBL] [Abstract][Full Text] [Related]
12. [Management of Ta, T1, and in situ bladder carcinoma: what is new?]. Irani J Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634 [TBL] [Abstract][Full Text] [Related]
13. Bladder cancer. Gwynn ES; Clark PE Curr Opin Oncol; 2006 May; 18(3):277-83. PubMed ID: 16552241 [TBL] [Abstract][Full Text] [Related]
14. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663 [TBL] [Abstract][Full Text] [Related]
15. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment]. Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268 [TBL] [Abstract][Full Text] [Related]
16. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737 [TBL] [Abstract][Full Text] [Related]
17. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T; Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609 [TBL] [Abstract][Full Text] [Related]